Alopecia Areata Associated With Dupilumab: National Database Study

July 2025 in “ Diagnostics ”

Tarun Sontam, Humaira Nfn, J. Li, Syed Maaz Nadeem, Katie Beier, Neil Jairath, Vignesh Ramachandran

dupilumab alopecia areata atopic dermatitis Th2 suppression Th1/Th17 pathways biologics

Studysummary In this retrospective study, researchers found a statistically significant increase in the risk of alopecia areata among atopic dermatitis patients using dupilumab compared to controls, suggesting the need for careful monitoring and further research on the drug's impact on alopecia areata. Our plain-language summary of this paper — not a Tressless recommendation.

This study examines the link between dupilumab, a treatment for atopic dermatitis (AD), and the risk of developing alopecia areata (AA) using data from over 300 million patient records. Analyzing 23,782 dupilumab users and an equal number of controls, the study found a statistically significant increased risk of AA in dupilumab users, with an odds ratio of 1.436. The findings suggest that dupilumab may trigger AA in some patients, possibly due to immune rebalancing, and emphasize the need for personalized treatment strategies and careful monitoring, especially for those with a history of autoimmune conditions. The study calls for further research to understand the mechanisms and improve treatment strategies for AD and AA.

View this study on mdpi.com →

Discuss this study in the Community →

Research cited in this study

12 / 12 results

research Two Phase 3 Trials of Baricitinib for Alopecia Areata

148 citations , March 2022 in “The New England Journal of Medicine”

In two phase 3 trials, this study found that oral baricitinib significantly improved hair regrowth compared to placebo in adults with severe alopecia areata after 36 weeks, though longer trials are needed to ascertain its long-term efficacy and safety.

research Early Onset of Alopecia Areata After Dupilumab Introduction in a Patient With Atopic Dermatitis

18 citations , October 2019 in “European Journal of Dermatology”

This article reviews treatment options for pityriasis rubra pilaris but reports no new clinical findings, often noting treatments as unsuccessful.

research Reactivation of Alopecia Areata After Dupilumab Therapy for Atopic Dermatitis

12 citations , August 2019 in “Dermatitis”

This case report describes a 42-year-old woman with atopic dermatitis, whose alopecia areata reactivated rapidly after starting dupilumab, possibly indicating an unrecognized adverse effect in AD patients.

research Alopecia Areata in 2 Patients Treated with Dupilumab: New Onset and Worsening

26 citations , July 2019 in “JAAD Case Reports”

This study reports two cases of hair loss outcomes in patients using dupilumab for atopic dermatitis, with one showing improvement in alopecia universalis and another experiencing worsening of alopecia totalis.

research Alopecia Areata in Severe Atopic Dermatitis Treated With Dupilumab

49 citations , December 2018 in “Journal of Investigational Allergology and Clinical Immunology”

Dupilumab may cause hair loss in some patients with severe atopic dermatitis.

research JAK Inhibitors for Treatment of Alopecia Areata

63 citations , July 2018 in “The journal of investigative dermatology/Journal of investigative dermatology”

In this review, the researchers reported that JAK inhibitors, originally approved by the FDA for other uses, have shown effectiveness in reversing hair loss in patients with moderate to severe alopecia areata, based on current preclinical and clinical studies.

research Alopecia Areata After Dupilumab for Atopic Dermatitis

53 citations , January 2018 in “JAAD case reports”

This report describes the case of a patient who developed alopecia areata within five weeks of starting treatment for atopic dermatitis with dupilumab.

research Alopecia Areata: Overview and Insights from January 2018

290 citations , December 2017 in “Journal of The American Academy of Dermatology”

This article reviews the epidemiology, clinical evaluation, and pathogenesis of alopecia areata and highlights recent advancements, but it does not report new clinical findings.

research Alopecia Areata Profiling Shows TH1, TH2, and IL-23 Cytokine Activation Without Parallel TH17/TH22 Skewing

176 citations , August 2015 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology”

This study identified a distinct cytokine activation signature in alopecia areata, involving TH2, TH1, IL-23, and IL-9/TH9 pathways, suggesting potential targeting strategies similar to those in psoriasis and atopic dermatitis.

research Alopecia Areata Is Driven by Cytotoxic T Lymphocytes and Is Reversed by JAK Inhibition

701 citations , August 2014 in “Nature medicine”

This study found that JAK inhibitors promote hair regrowth in both mice and human alopecia areata cases by blocking key immune pathways involved in disease development.

research Trichoscopy Update 2011

178 citations , December 2011 in “Journal of Dermatological Case Reports”

This review discusses the application of trichoscopy in diagnosing various hair and scalp diseases and reports no new clinical results; the authors emphasize its role as a non-invasive diagnostic tool.

research Genome-Wide Association Study in Alopecia Areata Implicates Both Innate and Adaptive Immunity

717 citations , June 2010 in “Nature”

This study identified key genetic regions associated with alopecia areata, highlighting both acquired and innate immune involvement, with a novel link to the upregulation of ULBP ligands in autoimmune disease.